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a  b  s  t  r  a  c  t
Foot-and-mouth  disease  viruses  (FMDV)  from  serotype  A exhibit  high  antigenic  diversity.  Within  the
Middle  East,  a strain  called  A-Iran-05  emerged  in  2003,  and  subsequently  replaced  the  A-Iran-96  and
A-Iran-99  strains  that  were  previously  circulating  in the region.  Viruses  from this  strain  did  not  sero-
logically  match  with  the  established  A/Iran/96  vaccine,  although  most  early  samples  matched  with  the
older  A22/Iraq  vaccine.  However,  many  viruses  from  this  strain  collected  after  2006  had  poor  serological
match  with  the  A22/Iraq  vaccine  necessitating  the development  of  a new  vaccine  strain  (A/TUR/2006).
More recently,  viruses  from  the  region  now  exhibit  lower  cross-reactivity  with  the  A/TUR/2006  antiserantigenic variation
apsid  sequence
pitopes
olyclonal antibodies
ntigenic  determinants
highlighting  the inadequacy  of the  serotype  A vaccines  used  in  the region.  In  order to  understand  the
genetic  basis  of these  antigenic  phenotypes,  we  have  determined  the  full  capsid  sequence  for 57  Middle
Eastern  viruses  isolated  between  1996  and  2011  and  analysed  these  data  in  context  of  antigenic  relation-
ship  (r1) values  that were  generated  using  antisera  to A22/Iraq  and  A/TUR/2006.  Comparisons  of  capsid
sequences  identiﬁed  substitutions  in  neutralising  antigenic  sites  (1,  2 and  4),  which  either  individually
or  together  underpin  these  observed  antigenic  phenotypes.
©  2013 The Authors. Published by Elsevier Ltd.       Open access under CC BY license.. Introduction
Foot-and-mouth disease (FMD) remains a globally impor-
ant livestock disease affecting cloven-hoofed animals. It remains
nzootic in many regions, especially in developing countries where
t imposes a trade barrier upon livestock and their products. The
ausative agent, FMD  virus (FMDV) has a rapid mutation rate and
xists in seven immunologically distinct serotypes, O, A, C, Asia
, SAT (Southern African Territories) 1, 2 and 3, each with a wide
pectrum of antigenically distinct subtypes.
FMDV is a single-stranded, positive-sense RNA virus (Genus
phthovirus, family Picornaviridae). The viral genome is about
.3 kb long, enclosed within a protein capsid. The capsid is com-
osed of 60 copies each of four different structural proteins
VP1-4); VP1-3 are surface exposed while VP4 is entirely internal.
∗ Corresponding author. Tel.: +44 1483 232441; fax: +44 1483 232448.
E-mail  address: mana.mahapatra@pirbright.ac.uk (M.  Mahapatra).
264-410X     ©   2013 The Authors Published by Elsevier Ltd  .     .  
ttp://dx.doi.org/10.1016/j.vaccine.2013.08.102
Open access under CC BY license.Crystallographic studies have identiﬁed the structure of the FMDV
capsid [1,2] and immunological epitopes have been mostly found
on surface-oriented interconnecting loops between structural ele-
ments. Studies employing monoclonal antibodies (mAb) have
identiﬁed antigenic sites by sequencing mAb  neutralisation resis-
tant (mar) mutants [3–9]. Of the ﬁve antigenic sites reported so
far for the most extensively studied serotype O, site-1 (G-H loop)
is linear and trypsin-sensitive whereas the others are conforma-
tional and trypsin-resistant. Equivalent neutralising antigenic sites
(except site 3) have also been identiﬁed for serotype A, with critical
residues present in equivalent positions [3–6,9].
Serotype A viruses are present on all continents where FMD  is
reported, and is antigenically diverse [10] often exhibiting poor
cross-protection [11]. In the Middle East (ME), a new variant, A-
Iran-05, was identiﬁed in samples collected from Iran in 2003
and subsequently spread to neighbouring countries [10] and North
Africa [12]. This genotype replaced the A-Iran-96 and A-Iran-99
genotypes that were previously circulating in the region; did not
cross-react with A/Iran/96 vaccine antisera and shared a closer anti-
genic relationship with the older A22/Iraq vaccine strain (v/s) [10].
However, many samples isolated after 2006 did not even match
with A22/Iraq v/s and so a new v/s, A/TUR/2006 was introduced.
From sequence data, Jamal and colleagues indicated candidate
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mino acid (aa) substitutions in the capsid that might have con-
ributed to these antigenic changes [13]. More recently, there is
vidence that viruses from the region now exhibit lower cross-
eactivity with the A/TUR/2006 antisera. The aim of this study was
o investigate the molecular basis of the antigenic variation in these
iruses using capsid sequences and their corresponding antigenic
elationship (r1) values.
.  Materials and methods
.1.  Cells and viruses
Fifty-seven  serotype A viruses from the ME  submitted to the
ood and Agriculture Organisation’s World Reference Laboratory
or FMD  (WRLFMD) at the Pirbright Institute were used in this study
Supplementary table). Two are the v/s A22/IRQ/24/64 (A22/Iraq)
nd A/TUR/2006 that were originally isolated in Iraq and Turkey, in
964 and 2006 respectively; the 55 other viruses were isolated over
 ﬁfteen year period (1996–2011). These viruses were from seven
E countries, Turkey (n = 17), Iran (n = 26), Iraq (n = 2), Pakistan
n = 5), Afghanistan (n = 4), Saudi Arabia (n = 1) and Jordan (n = 2)
Supplementary table). These samples were derived from cattle
pithelial tissues (except one of ovine origin), and were initially
rown in primary bovine thyroid cells with subsequent passage
n either BHK-21 or IB-RS2 cells. Stocks of virus were prepared by
nfecting IB-RS2 cell monolayers and were stored as clariﬁed tissue
ulture harvest at −70 ◦C until required.
Supplementary data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/j.vaccine.
013.08.102.
.2.  Polyclonal serum
Antisera  were prepared against serotype A FMD  viruses
A22/Iraq and A/TUR/2006) by immunising ﬁve cattle per v/s with
nactivated, puriﬁed 146S FMD  virus particles in ISA-206 adjuvant.
ulk blood was collected on 21 day post-vaccination for prepara-
ion of sera. For each antigen, a pool of sera from ﬁve animals was
sed in the serological tests. The A22/Iraq and A/TUR/2006 anti-
era exhibited equivalent homologous titres (log10 2.43 and 2.54,
espectively) by virus neutralisation test (VNT).
.3. Two-dimensional micro neutralisation assay (2D-VNT)
The  2D-VNT was carried out using the 21-day post-vaccination
era following established methodology [14]. Antibody titres were
alculated from regression data as the log10 reciprocal antibody
ilution required for 50% neutralisation of 100 tissue culture
nfective units of virus (log10SN50/100 TCID50). The antigenic rela-
ionship of viruses based on their neutralisation by antibodies is
iven by the ratio: ‘r1 ′ = neutralising antibody titre against the het-
rologous virus/neutralising antibody titre against the homologous
irus. Differences in the r1-values obtained by the polyclonal anti-
erum were evaluated according to standard criteria [15].
.4.  Nucleotide (nt) sequencing and analysis of the sequence data
The  sequences of the entire capsid coding region (P1) of selected
iruses were generated. RNA extraction from the cell culture grown
iruses and reverse transcription (RT) were performed as described
16]. PCR was carried out using the “KOD hot-start DNA poly-
erase” kit (Novagen) as recommended by the manufacturer, usinghe forward primer L463F (5′-ACCTCCRACGGGTGGTACGC-3′) and
ne of the reverse primers NK72 (5′-GAAGGGCCCAGGGTTGGACTC-
′) or EUR2B52R (5′-GACATGTCCTCCTGCATCTGGTTGAT-3′). PCR
roducts were puriﬁed using the QIAquick PCR puriﬁcatione 32 (2014) 631– 638
kit  (Qiagen) according to the manufacturer’s instructions and
sequenced using BigDye® Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, Carlsbad, CA, USA) using the PCR primers
and additional internal sequencing primers (sequences available on
request). Sequences (from the ABI 3730 machine) were assembled
and analysed using SeqMan II (DNAStar Lasergene 8.0). Nucleotide
sequences of the viruses were aligned using the CLUSTAL X multiple
sequence alignment program [17] and the predicted aa sequences
were translated using BioEdit 7.0.1 [18]. Alignments were used
to construct distance matrices using the Kimura 2-parameter
nucleotide substitution model [19] as implemented in the pro-
gramme  MEGA 4.0 [20].
2.5.  Bayesian phylogenetic analysis
The complete P1 sequence of the viruses belonging to the A-
Iran-05 strain (n = 51) were aligned and subjected to jModelTest
0.1.1 [21]. The general time reversible (GTR) model for substitution
model with combination of gamma  distribution and proportion
of invariant sites (GTR + I + G) was  found to be the best model for
the Bayesian analysis of the sequence dataset. Analysis was  per-
formed using the BEAST software package v1.5.4 [22] with the
maximum clade credibility (MCC) phylogenetic tree inferred from
the Bayesian Markov Chain Monte Carlo (MCMC) method. The age
of the viruses were deﬁned as the date of sample collection. In
BEAUti v1.5.4, the analysis utilised the GTR + I + G model to describe
rate heterogeneity among sites. In order to accommodate variation
in substitution rate among branches, a random local clock model
was chosen for this analysis [23]. BEAST output was viewed with
TRACER 1.5 and evolutionary trees were generated in the FigTree
program v1.3.1.
2.6.  Data analysis
The  proportion of synonymous substitutions per potential
synonymous site and the proportion of non-synonymous substitut-
ions per potential non-synonymous site were calculated by the
method of Nei and Gojobori [24] using the SNAP program
(www.hiv.lanl.gov). The aa variability of the capsid region of the
A-Iran-05 viruses was determined as described by Valdar [25]. Sta-
tistical analyses used Minitab release 12.21 software.
3. Results and discussion
The  A-Iran-05 viruses, ﬁrst detected in Iran [10], spread to
neighbouring countries in the ME  [10,12,13], and spawned sub-
lineages over the next seven years. Most sub-lineages died out,
whereas a few persisted and became dominant, and some are
still circulating. In this study, we have focussed mainly on three
sub-lineages, namely ARD-07, AFG-07 and BAR-08. ARD-07, ﬁrst
detected in Ardahan, Turkey in August 2007 was the main cir-
culating strain in Turkey during 2007–2010. However, it has not
been detected in samples received in WRLFMD, Pirbright from
Turkey during 2011–2012. AFG-07, ﬁrst isolated from a bovine
sample in Afghanistan in 2007 has spread to other neighbouring
countries such as Bahrain, Iran, Pakistan and Turkey. BAR-08, ﬁrst
detected in a bovine sample in the Manama region of Bahrain
in 2008 has spread to other countries such as Iran, Pakistan
and Turkey. This sub-lineage has also jumped to North African
countries, such as Libya in 2009 [12] and Egypt in 2010 and 2011
(http://www.wrlfmd.org), probably because of trade links with ME
countries.  Evolution of the serotype A viruses in the ME  has resulted
in the appearance of further sub-lineages like HER-10 and SIS-10.
These sub-lineages have gained dominance over the others and
S. Upadhyaya et al. / Vaccine 32 (2014) 631– 638 633
Fig. 1. (A) Antigenic relationship (r1) values of pre-A-Iran-05 viruses. A22/Iraq (white bars) and A/TUR/2006 (black bars). The horizontal dotted line indicates the cut-off
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salue of 0.3, above which the vaccine is considered to be a good match. (B) Bayesi
white bars) and A/TUR/2006 (black bars) antisera. The sub-lineages deﬁned by WR
ave been reported to be actively circulating in this region in years
011 and 2012 (http://www.wrlfmd.org)..1.  Serological characterisation of the type A viruses
The cross-reactivity of the type A viruses from the ME  were mea-
ured by 2D-VNT using A22/Iraq and A/TUR/2006 post-vaccinationylogenetic tree of the A-Iran-05 viruses and respective r1-values against A22/Iraq
 on the basis of VP1 sequences are labelled on the respective branches.
sera.  The six pre-2004 viruses (A-Iran-96/non-designated strains)
exhibited weak cross-reactivity with these antisera except A22/Iraq
and A/IRN/6/2002 that cross-reacted with the A22/Iraq antisera
(Fig. 1A). For the A-Iran-05 strain, viruses isolated in early years
reacted well with A22/Iraq anti-sera, whereas isolates after 2006
exhibited lower reactivity (Fig. 1C). Most of these viruses exhib-
ited higher cross-reactivity with the newer A/TUR/2006 vaccine
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Table 1A
Capsid nucleotide positions with three nucleotide substitutions and associated
amino  acid changes relative to A/IRN/07/2004 virus. The number of isolates in which
these changes were observed are shown in parenthesis.
Capsid nucleotide position Codon position Amino acid substitutions
1119 VP3 70 D → A(2)/E(7)/N(1)
1305 VP3 132 T → N(16)/A(1)
1521 VP3 204 V → A(1)
145–152, 168–171 and 192–204) had dN/dS ratio of >1 indicative
of sites under strong positive selection.34 S.  Upadhyaya et al. / V
ntisera. However, viruses from Iran, Pakistan and Turkey
elonging to sub-lineages BAR-08 and ARD-07 exhibited lower
ross-reactivity with the A/TUR/2006 antisera (Fig. 1C).
.2.  Genetic characterisation of the type A viruses
The complete capsid sequence of 57 serotype A viruses gen-
rated in this study were 2205 nt long except A/IRQ/108/2002
A-Iran-96 strain) that had a 3-nt deletion at position 1984–1986
f P1, resulting in deletion of an aa at position VP1-138 in the
–H loop which has been reported to be a dominant antigenic
ite [4]. When compared to the sequence of the A22/Iraq v/s there
as 17.0–20.6% nt variation between these viruses: A/IRN/03/96
haring the closest nt identity and A/IRN/45/2011 being the most
ariable. Analysis of the capsid aa sequences revealed 6.1–18.1%
ariation, A/IRN/30/2005 and A/IRN/05/2006 having the closest,
nd A/IRN/45/2011 having the lowest aa identity, respectively. Sim-
larly, when compared to the capsid sequence of the A/TUR/2006
/s, the nt variability was found to vary from 0.8 (A/TUR/02/2006)
o 19.3% (A/TUR/04/2003) with a 0.5 (A/IRN/07/2006) to 9.1%
A/TUR/04/2003) variation at the aa level.
Phylogenetic analysis of the capsid sequences revealed all the
iruses belong to the ASIA topotype within serotype A FMDV. The
iruses isolated from 2004 onwards formed a new genetic strain, A-
ran-05, distinct from previous virus strains reported to be present
n the region, similar to an earlier report [10]. Various sub-lineages
ithin the A-Iran-05 strain have been deﬁned based on the anal-
sis of VP1 sequences. The samples used in this study included 9
amples from BAR-08, 11 from AFG-07, 4 from ARD-07 and one
ach from ESF-10, FAR-09, QAZ-11 and EZM-07 (Supplementary
able). The sub-lineages, BAR-08 and AFG-07 shared a common
ncestor which evolved into two distinct sub-lineages over time,
hereas most of the contemporary viruses gradually died out.
/IRN/78/2009 belongs to sub-lineage FAR-09 that has evolved
rom the AFG-07 sub-lineage, and is currently circulating in the
egion. A/AFG/12/2011 has not been assigned a sub-lineage yet,
owever, shares a common ancestor (AFG-07 sub-lineage) with
/IRN/78/2009. This pattern is also consistent with that observed
hen phylogenetic trees are drawn using only VP1 sequences (data
ot shown). Additional phylogenetic analysis of seven A-Iran-05
solates from Pakistan and Afghanistan [13] revealed that the iso-
ates belonging to AFG-07 or BAR-08 sub-lineages cluster with
equences of viruses from the same sub-lineage used in this study
data not shown).
.3.  Rate of nucleotide substitution per site
From the BEAST analysis using a random local molecular
lock, the rate of substitution of all the nt changes in the cap-
id coding region of the A-Iran-05 viruses was estimated to be
.06 × 10−2/site/year (95% HPD 9.53 × 10−3 to 1.05 × 10−2). This is
imilar to the report (1.12 × 10−2/site/year) for VP1 sequences of
-Iran-05 viruses [13]; but higher than those reported by others
26–32]. The high evolutionary rate of serotype A viruses in the ME
s resulting in emergence of new variants in the region.
.4.  A-Iran-05 viruses
An  unbiased analysis of capsid sequences of the 51 A-Iran-05
iruses revealed 692 nt substitutions at 637 sites distributed across
he region (Fig. 1B). Out of these, 80.05% of nt substitutions were
ound to be synonymous (silent) and 19.95% were non-synonymous
non-silent). Forty seven sites were identiﬁed to have been sub-
tituted twice and four were substituted three times. At one site
VP2-134) the ﬁrst two bases of the codon were mutated encod-
ng 5 different aa (P->T/S/L/H). This residue is located very close to1656 VP1 28 Q → H(20)
residues VP2-132 and 133 that were reported as critical by mar-
mutant studies for A10 virus [9]. In addition, the residue at this
position has been reported to strongly inﬂuence the binding of anti-
genic site-2 mAbs in serotype O viruses [16]. Out of the four sites
with three nt substitutions (encoding 2–4 aa residues), three were
present in VP3 and one in VP1 (Table 1A).
The analysis of the capsid aa residues of A-Iran-05 viruses
revealed 140 substitutions at 101 sites across the capsid (Fig. 2A)
with some sites having 2–5 alternate aa (Table 1B). Interestingly,
sequences for VP1-204 encoded ﬁve different aa and exhibited nt
changes at all the three positions within the codon as did VP1-
196, with changes at all the three positions of the codon giving
rise to four alternative aa. In addition, the non-synonymous nt
substitutions were not equally distributed across the capsid cod-
ing regions: there were several local areas where the dN/dS ratio
was higher than in other parts of the sequence alignment (Fig. 2B).
One region in VP3 (57–65), two in VP2 (75–76 and 130–134) and
eight regions in VP1 (52–53, 83–84, 92–105, 131–132, 137–141,Fig. 2. (A) Cumulative changes in capsid coding regions of A-Iran-05 viruses. The
black line indicates total cumulative nucleotide changes, the grey line, cumulative
amino  acid changes. (B) dN/dS of capsid of A-Iran-05 viruses. The vertical black
dotted line indicates gene junctions.
S. Upadhyaya et al. / Vaccine 32 (2014) 631– 638 635
Fig. 3. (A) Capsid amino acid variability of A-Iran-05 viruses. The vertical black dotted line indicates gene junctions. (B–D) 3D structure of Type A protomer, modelled using
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.5. Amino acid variability of the capsid of the A-Iran-05 viruses
Investigation of aa variability across the capsid of the A-Iran-05
iruses revealed VP4 to be highly conserved and VP1 least con-
erved (Fig. 3A); similar to an earlier report [13]. The residues with
 score greater than 0.75 (3 in VP2, 6 in VP3 and 12 in VP1) are
hown in Fig. 3B-D indicating that over 50% of the residues with
ery high variability scores were present in VP1 (Fig. 3A). All these
esidues were found to be surface-exposed, except one residue in
he N-terminus of VP1 (position 28) and one in N-terminus of VP3
position 8) (Fig. 3C and D).
.6. Correlating genotype to antigenic phenotypeA number of aa changes were observed between the v/s and ﬁeld
solates, however no linear correlations between the r1-values and
he total number of aa changes in the capsid encoding regions were
able 1B
apsid positions where multiple amino acid substitutions were observed. The number of
Viral protein Positions with three alternative
amino  acid residues
Positi
amino
VP4 77 (2) – 
VP2 39 (2), 56 (3), 79 (9) – 
VP3
8 (17), 25 (3), 59 (12)
70 (1061  (2), 132 (17), 139 (3)
175 (3), 220 (22)
VP1
4 (2), 45 (14), 108 (4) 24 (4)
139  (2), 140 (5), 149 (23) 99 (12
154  (2), 171 (3)sidues (with a score of more than 0.75) highlighted. VP1 residues (red), VP3 (blue),
e references to colour in this ﬁgure legend, the reader is referred to the web  version
observed (data not shown). When compared to the A22/Iraq vac-
cine, these viruses had more than 40 aa changes in the capsid region,
whilst about 35% of these had r1 values above 0.3 indicating a good
match. This indicates that a large proportion of the substitutions
are neutral and only a few, located at particular capsid positions
impact on the antigenic nature of the virus. Similar analyses were
also carried out to study if the r1-values correlated with the number
of aa changes in each of the individual structural proteins (VP1-4);
however no linear correlation was observed (data not shown).
3.7.  Comparison between A22/Iraq, A/TUR/2006 v/s and BAR-08
ﬁeld  isolatesIn  vitro testing of viruses belonging to the BAR-08 sub-
lineage with either A22/Iraq or A/TUR/2006 antisera generated
low r1-values indicating lower expected protection. The cap-
sid aa sequences of these viruses, including sequences for two
 isolates in which these changes were observed are shown in parenthesis.
ons with four alternative
 acid residues
Positions  with ﬁve alternative
amino  acid residues
–
134 (18)
)
–
, 43 (23), 96 (16) 204 (6)
), 141 (27), 196 (22) –
636 S.  Upadhyaya et al. / Vaccine 32 (2014) 631– 638
VP2
61       70        80        90        100
....|....|....|....|....|....|....|....|
A22/IRQ24/64 FFKKHLFDWTPDKAFGHLEKLELPTDHKGVYGHLVDSFA Y
A/TUR/20/06 ..........T.......G......E..............
A/IRN/02/09 ...EY. ....T.......V......E...........Y. .
A/IRN/06/09 ...EY.....T.......V......E...........Y. .
A/IRN/25/09 ...EY.....T.......V......E...........Y. .
A/IRN/37/09 ...EY.....T.......V......E...........Y. .
A/IRN/63/09 ....Y.....T.......V......E...........Y..
A/PAK/04/09 ...EY.....T.......V......E...........Y. .
A/IRN/36/10 ...EY.....T.......V......E...........Y..
A/PAK/13/10 ....Y.. ...T..............E...........Y. .
A/SIN/PAK/L693/2009/JF721436 ....Y.....T.......V......E...........Y. .
A/SAR/AFG/L1434/2009/JF721438 ..........T.......V......E...........Y..
VP3
55       64        74
....|....|....|....|....|
A22/IRQ24/64 LCFDEGKPYVVTRTDEQRLLAKFD V
A/TUR/20/06 ....D..........D........ .
A/IRN/02/09 ....N.....E....D........ .
A/IRN/06/09 ....N.....E....D........ .
A/IRN/25/09 ....N.....E....D........ .
A/IRN/37/09 ....N.....E....D.....R.. .
A/IRN/63/09 ....N.....E....D........ .
A/PAK/04/09 ....N.....E....D. ....... .
A/IRN/36/10 ....N.....E....D........ .
A/PAK/13/10 ....N.....E....DR....... .
A/SIN/PAK/L693/2009/JF721436 ....N.....E....D........ .
A/SAR/AFG/L1434/2009/JF721438 ....N.....E....D........ .
205      214
....|....|....|..
A22/IRQ24/64 SAGKDFELRLPIDPRS Q
A/TUR/20/06 ...............T .
A/IRN/02/09 ...............A .
A/IRN/06/09 ...............A .
A/IRN/25/09 ...............A .
A/IRN/37/09 ...............A .
A/IRN/63/09 ...............A .
A/PAK/04/09 ...............A .
A/IRN/36/10 ...............A .
A/PAK/13/10 ...............A .
A/SIN/PAK/L693/2009/JF721436 ...............A .
A/SAR/AFG/L1434/2009/JF721438 ...............A .
VP1
25       34 44
....|....|....|....|....|
A22/IRQ24/64 QRRQHTDVTFIMDRFVKIQNLNPT H
A/TUR/20/06 ........G.........SPVS.. .
A/IRN/02/09 ...H....G.........NPAS.. .
A/IRN/06/0 9 ...H....G.........NPAS.. .
A/IRN/25/09 ...H....G.........NPAS.. .
A/IRN/37/09 ...H....G.........NPAS.. .
A/IRN/63/09 ...H....G.........KPAS.. .
A/PAK/04/09 ...H....G.........NPAS...
A/IRN/36/10 ...H....G.........NPAS.. .
A/PAK/13/10 ...H....G.........EPAS.. .
A/SIN/PAK/L693/2009/JF721436 ...H....G.........NPAS.. .
A/SAR/AFG/L1434/2009/JF721438 ...H....G.........NPAG.. .
60       69        79        89
....|....|....|....|....|....|
A22/IRQ24/64 GLVGALLRAATYYFSDLEIVVRHDGNLTW V
A/TUR/20/06 A............................ .
A/IRN/02/09 A....F.................E..... .
A/IRN/06/09 A....F.................E..... .
A/IRN/25/09 A....F.................E..... .
A/IRN/37/09 A....F.................E......
A/IRN/63/09 A....F.................E..... .
A/PAK/04/09 A....F.................E..... .
A/IRN/36/10 A....F.................E..... .
A/PAK/13/10 A....F.. ...............E..... .
A/SIN/PAK/L693/2009/JF721436 A....F.................E..... .
A/SAR/AFG/L1434/2009/JF721438 A....F.................E..... .
130      139       149
....|....|....|....|.... |
A22/IRQ24/64 YNGTSKYSAGGTGRRGDLGPLAAR V
A/TUR/20/06 ...V....TT.N.......S.... .
A/IRN/02/09 ...V....TT.G............ .
A/IRN/06/09 ...V....TTSG.......S.... .
A/IRN/25/0 9 ...V....TTSG......RS.... .
A/IRN/37/09 ...V....TT.G............ .
A/IRN/63/09 ...V....TTDG............ .
A/PAK/04/09 ...V....TT.G.......S.... .
A/IRN/36/10 ...VN...TT.G.......S.... .
A/PAK/13/10 ...V....TT.G.......S.... .
A/SIN/PAK/L693/2009/JF721436 ...V....TT.G.......S.... .
A/SAR/AFG/L1434/2009/JF721438 ...V....TT.G.......S.... .
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cig. 4. Capsid amino acid substitution in BAR 08 viruses compared to A22/Iraq an
/SAR/AFG/L1434/2009/JF721438) were extracted from GenBank. The residues wi
iruses.
solates previously reported [13], were analysed further to under-
tand the changes in the antigenicity of these viruses. As most of
hese viruses do not cross-react with the antisera of either of the
/s, we speciﬁcally looked for aa residues in the ﬁeld isolates which
ere different from those of both the v/s (Fig. 4). A total of 11
a residues were identiﬁed; three residues (VP1-45, 65 and VP3-
9) were indicated in a similar study [13]. Three residues were
ig. 5. 3D structure of a type A protomer, modelled using O1 BFS co-ordinates (1FOD, redu
een  identiﬁed by mar  mutant studies are highlighted; VP1 residues (red), VP2 (green), VP
n  BAR-08 viruses that has also been identiﬁed by mar-mutant studies (cyan). (A) Cartoo
olour  in this ﬁgure legend, the reader is referred to the web  version of the article.)UR/2006 v/s. The sequences of two  isolates (A/SIN/PAK/L693/2009/JF721436 and
 change are boxed. The grey box in VP2 indicates substitutions in nine out of 10
eliminated  as being either completely (VP1-28) or partly (VP2-98)
on the internal surface of the virion (Fig. 5C), or completely (VP1-
65) buried in the structure; though Jamal and colleagues indicated
substitution of VP1-65 may  change the surface structure [13]. The
remaining eight residues (VP1-45, 83, 141; VP2-65, 79; VP3-59, 65,
220) were surface-exposed (Fig. 5B) and are therefore good can-
didates to explain the inability of the antisera to cross-react with
ced) [2] with type A residues highlighted. The critical amino acid residues that have
3 (blue); aa residues identiﬁed in BAR-08 viruses (magenta), aa residues identiﬁed
n; (B) External surface; (C) Internal surface. (For interpretation of the references to
accin
t
i
b
r
[
A
p
c
B
8
t
t
s
i
t
r
r
a
v
s
3
i
s
H
e
c
w
t
w
n
a
[
i
p
w
a
t
B
i
r
m
o
a
h
5
t
f
n
o
c
p
i
c
e
l
A
b
u
[
[
[
[
[
[
[
[
[
[
[
[
[S. Upadhyaya et al. / V
he ﬁeld isolates. The substitutions in VP2-65 and 79 were recorded
n nine out of 10 isolates studied. We  excluded VP1-45 because (i)
oth the residues are hydrophobic; (ii) this/adjacent residues were
eported to be part of antigenic site-3 in case of serotype O viruses
7] and SAT 1 [33], however this has never been reported in serotype
 mar-mutant studies; (iii) this residue is also picked up by epitope
rediction software, however, mutation of this residue in a cDNA
lone did not have much impact on the antigenicity of the virus (F.
ari and M.  Mahapatra, unpublished results). Three residues VP1-
3, 141 and VP3-59 (shown in cyan in Fig. 5B) have been reported
o be critical in serotype A mar-mutant studies [3–5,9]. A change in
hese residues may  affect the overall conformation of the viral cap-
id and thereby alter the antigenicity of the virus. VP3-220 is located
n close proximity to the C-terminus of VP1 of an adjacent pro-
omer, and in close vicinity to residue VP3-218, which was  recently
eported to be critical in serotype Asia 1 [8]. In addition, all these
esidues were highly variable among the A-Iran-05 viruses (Fig. 2)
nd four of these, namely VP1-83, 141, VP3-59 and 65 exhibited
ery high dN/dS values (2, 2, 4.5 and 1.9, respectively) indicating
trong positive selection.
.8.  Comparison between A/TUR/2006 v/s and ARD-07 ﬁeld
solates
The  four serotype A viruses (isolated from Turkey) of ARD-07
ub-lineage were found to cross-react with the A/TUR/2006 v/s.
owever, two recent viruses (A/TUR/7/2009 and A/TUR/20/2010)
xhibited comparatively lower reactivity with these antisera. The
apsid aa sequence of these four viruses along with that of the v/s
ere aligned and analysed further leading to the identiﬁcation of
wo residues, VP1-24 (A-V) and VP2-70 (D-E). VP1-24 is internal,
hereas VP2-70 is present on the outer surface of the capsid (data
ot shown). In case of A5 virus, adjacent residues like VP2-72 (D-N)
nd 79 (Q-G/V) have been reported to be critical for mAb  binding
6]. Moreover VP2-70 has been reported to be critical in neutralis-
ng antigenic site 2 of serotype O viruses [7]. In addition, epitopes
resent in this area have recently been reported to be dominant
ithin the polyclonal response of serotype O vaccinated animals
nd mutations in this area resulted in signiﬁcant reduction in neu-
ralising antibody titres [34].
In summary, analysis of serology and capsid sequence data of
AR-08 and ARD-07 viruses revealed aa changes involving neutral-
sing antigenic sites 1, 2 and 4 of serotype A viruses that could be
esponsible for the antigenic variation in these viruses. Targeted
utagenesis studies involving a cDNA clone could conﬁrm these
bservations. A consequence of the high rate of evolution in FMDV
nd emergence of new sub-lineages of serotype A viruses, the ME
as required the regular development of new v/s typically every
–10 years. Therefore, close monitoring of the outbreak strains in
he region is essential to enable appropriate vaccines to be selected
or use in FMD  control programmes; and the need to develop a
ew v/s should be identiﬁed in a timely fashion to prevent future
utbreaks. In such situations where the match between v/s(s) and
irculating ﬁeld viruses is suboptimal, other steps that improve
opulation immunity become especially important, such as ensur-
ng the quality and potency of the vaccines; correct targeting and
overage of vaccines; the use of booster doses in a timely manner,
specially in young animals and those susceptible livestock that are
ikely to be traded.
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